Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working
An experimental therapy has demonstrated efficacy in eliminating aggressive pancreatic tumors, addressing a major obstacle in solid tumor treatment. Many cancers protect themselves using a dense barrier of scar-like tissue that blocks cancer-killing T cells from reaching the malignancy. This physical shield explains why standard immunotherapy drugs typically help only a minority of patients diagnosed with pancreatic, breast, colon, and lung cancers. Researchers are working to overcome these defense mechanisms to improve patient outcomes and enhance immune system memory against recurrent disease.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Solid tumors including pancreatic, breast, colon, and lung cancers protect themselves with a dense wall of scar-like tissue.
- ✓ The scar-like tissue wall keeps the immune system's cancer-killing T cells out of the tumor.
- ✓ Immunotherapy drugs help only a minority of people with solid tumors because of these protective barriers.
What changed
Recent data highlights an experimental drug that eliminates aggressive pancreatic tumors and enhances immune system memory by tackling the protective walls surrounding solid cancers.
Live updates
-
Experimental Drug Targets Pancreatic Tumor Barriers
An experimental therapy has demonstrated efficacy in eliminating aggressive pancreatic tumors, addressing a major obstacle in solid tumor treatment. Many cancers protect themselves using a dense barrier of scar-like tissue that blocks cancer-killing T cells from reaching the malignancy. This physical shield explains why standard immunotherapy drugs typically help only a minority of patients diagnosed with pancreatic, breast, colon, and lung cancers. Researchers are working to overcome these defense mechanisms to improve patient outcomes and enhance immune system memory against recurrent disease.
Why it matters
Pancreatic cancer remains exceptionally difficult to treat due to physical barriers and rapid drug resistance mechanisms. Previous research revealed that proteins shifting shapes drive drug tolerance in targeted therapies like daraxonrasib. Understanding how experimental treatments interact with tumor tissue barriers and cellular adaptability is critical to preventing clinical relapse.
What is confirmed
- Solid tumors including pancreatic, breast, colon, and lung cancers protect themselves with a dense wall of scar-like tissue.
- The scar-like tissue wall keeps the immune system's cancer-killing T cells out of the tumor.
- Immunotherapy drugs help only a minority of people with solid tumors because of these protective barriers.
What to watch next
- Further clinical data on the experimental drug's ability to penetrate tumor tissue
- Results from trials measuring long-term immune system memory against pancreatic cancer
confidence 100%Sources used for this update (6)
- jen.jiji.com — Vacarini (Unipol): "AI is changing the way information is consumed"
- jen.jiji.com — Mushroom poisoning, what to know and which ones to choose. Experts: "Never trust home remedies"
- medicalxpress.com — Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory
- www.curecancerwithai.com — Promising Experimental Drug Demonstrates Potential to Combat ...
- jen.jiji.com — Cancers: Aiom, 'there is no test that excludes every risk, yes to screening no to inappropriate exams' (2)
- jen.jiji.com — Monica Busetto is free again, ok to the request for review of the trial for the nurse convicted of her neighbor's murder
-
Clues to Why Pancreatic Cancer Drug Stops Working
Researchers found that proteins constantly shifting shapes may drive drug tolerance in KRAS-targeted cancer therapies, including daraxonrasib, which doubled median overall survival for pancreatic cancer patients but often leads to relapse.
Why it matters
Pancreatic cancer is aggressive and historically resistant to treatment. Daraxonrasib, a KRAS-targeted therapy, was FDA-approved in August 2026 for adults with metastatic pancreatic adenocarcinoma. The disease often relapses, and understanding resistance mechanisms is crucial.
What is confirmed
- Daraxonrasib was FDA-approved on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma.
- The recommended dose of daraxonrasib is 300 mg once daily by tablet until progression or unacceptable toxicity.
- KRAS inhibitors represent one of the most rapidly evolving areas of precision oncology.
Still unconfirmed
- Verastem plans to launch a Phase III trial for pancreatic cancer.
What to watch next
- Further studies on combination strategies for KRAS inhibitors
- Evidence on the role of proteins in drug tolerance
- Updates on Verastem's Phase III trial
confidence 90%Sources used for this update (4)
- www.research.va.gov — VA Research News Briefs
- www.smartcancer.org — Latest Breakthroughs on Pancreatic Cancer 2026: FDA Approves ...
- www.fool.com — Verastem (VSTM) Q3 2026 Earnings Call Transcript
- cancer.aestheticsadvisor.com — KRAS Inhibitors (2026): The Complete Guide to Targeted ...
-
Researchers Identify Strategy to Combat KRAS-Targeted Drug Resistance
Researchers at Roswell Park Comprehensive Cancer Center have identified a strategy to overcome treatment resistance in KRAS-targeted cancer therapies. This preclinical study, published in Cancer Research, addresses a primary challenge for drugs like daraxonrasib, which saw FDA approval in August 2026. While daraxonrasib has doubled median overall survival for pancreatic cancer patients, the disease often relapses. Current research suggests that drug tolerance may be driven by proteins that constantly shift shapes rather than genetic mutations alone, offering a potential path to prevent tumors from becoming resistant to these oral pan-RAS inhibitors.
Why it matters
Pancreatic cancer is often diagnosed at an advanced stage and has a five-year survival rate of approximately 13%. The introduction of daraxonrasib represents a shift toward targeted oral treatments for this malignancy. Understanding why these therapies stop working is essential to improving long-term patient outcomes.
What is confirmed
- Pancreatic cancer has an overall five-year survival rate of approximately 13%.
- Daraxonrasib is an FDA-approved oral pan-RAS inhibitor for pancreatic cancer.
- Roswell Park Comprehensive Cancer Center researchers published a preclinical study in Cancer Research on overcoming KRAS-targeted therapy resistance.
Still unconfirmed
- Rapid and reversible drug tolerance in cancer cells may be driven by the constantly shifting shapes of proteins rather than just genetic mutations.
- Referral gaps, payer delays, and pharmacy bottlenecks are stalling access to breakthrough cancer drugs.
What to watch next
- Clinical trial results validating the Roswell Park preclinical strategy for overcoming KRAS resistance.
- Peer-reviewed data on whether protein shape-shifting is a primary driver of daraxonrasib relapse.
confidence 90%Sources used for this update (12)
- www.onclive.com — A New Era in Pancreatic Cancer Treatment: Daraxonrasib Shakes ...
- www.geneonline.com — Oral Pan-RAS Inhibitors: What’s Next for Pancreatic Cancer ...
- medicalxpress.com — Researchers identify strategy for overcoming resistance to ...
- www.ajmc.com — Logistics, Payer Rules, and Care Coordination Shape Access to ...
- www.henryford.com — New FDA-Approved Treatment, Daraxonrasib, Is Game-Changing ...
- jen.jiji.com — Biorepack: "45 thousand tons of packaging transformed into compost every year"
- jen.jiji.com — Vaccines: Signorelli (UniSr): "HPV coverage too low in the South, a change of pace is needed"
- Bioengineer.org — Cancer's shape-shifting proteins may explain why drugs stop ...
- davidbakke.substack.com — Checkpoint Resistance Is Not One State — And That Changes ...
- news.med.miami.edu — How Pancreatic Cancer Research Is Revealing New Treatment ...
- pancreatic.org — The Latest Advancements in Pancreatic Cancer Research on ...
- health.yahoo.com — Beyond Chemotherapy: Emerging Treatments for Pancreatic Cancer
-
Researchers Target Why Successful RAS Inhibitors Eventually Fail
Pancreatic cancer remains one of the deadliest US malignancies with a five-year relative survival rate of just 13%. Although targeted oral treatments like the pan-RAS inhibitor daraxonrasib have achieved significant milestones by doubling median overall survival and securing FDA approval in August 2026, patients frequently relapse. New scientific studies are examining why tumors develop resistance over time. Researchers are exploring combination approaches and tumor behavior patterns, such as adaptive constraint and collapse-dominant control, to understand why initially effective treatments eventually stop working.
Why it matters
Pancreatic cancer is historically difficult to treat because it involves mutations in genes previously considered undruggable. The approval of targeted therapies provides new options for patients with advanced disease. However, achieving long-term disease control requires moving beyond initial tumor shrinkage to understand how cancer cells reshape their genetic makeup to evade therapy.
What is confirmed
- Pancreatic cancer is the third-leading cause of cancer death in the US and has a five-year relative survival rate of just 13%.
- A phase 3 trial of the pan-RAS inhibitor daraxonrasib doubled median overall survival in previously treated metastatic pancreatic cancer, leading to FDA approval on August 26, 2026.
Still unconfirmed
- Combination approaches involving Roswell Park researchers may successfully overcome resistance to RAS cancer drugs.
What to watch next
- Results from combination clinical trials testing how to prevent or overcome resistance to RAS inhibitors.
- Further research into whether buffered suppression or adaptive constraint explains why tumors relapse after targeted therapy.
confidence 90%Sources used for this update (7)
- nypost.com — Game-changing new treatment just arrived for one of the ...
- Bioengineer.org — RAS Inhibitor Daraxonrasib Redefines Pancreatic Cancer Treatment After FDA Approval
- pancan.org — In Her Dad’s Memory: A Scientist’s Mission to Change the Story of Pancreatic Cancer
- www.roswellpark.org — Roswell Park team targets resistance to RAS cancer drugs
- www.gadgetreview.com — The Drug That Finally Cracked Pancreatic Cancer’s ...
- www.nature.com — Rethinking therapeutic durability in cancer | Oncogene - Nature
- ptmasterguide.com — Why Some Cancer Drugs Stop Working - PT Master Guide
-
Experimental Pill Shrinks Tumors in 41% of Pancreatic Cancer Patients
Verastem reported that its experimental KRAS G12D pill shrank tumors in 41% of 22 previously treated pancreatic cancer patients. This development follows the FDA approval of daraxonrasib, a pill that extends survival in metastatic cases. While these targeted therapies offer new options, researchers continue to investigate why cancer cells reshape their genetic makeup to resist treatment over time. New research into NEAT1-built nuclear structures called paraspeckles has also identified a metabolic weakness in certain cancer subtypes that may guide future therapy combinations.
Why it matters
Pancreatic cancer is often diagnosed after it has spread, making early detection a critical priority for physicians. Targeted therapies focusing on RAS inhibition aim to provide more personalized treatment than traditional chemotherapy.
What is confirmed
- Verastem's KRAS G12D pill shrank tumors in 41% of 22 previously treated pancreatic cancer patients.
- The FDA approved a pill that extends survival in metastatic pancreatic cancer.
- Researchers presented data on daraxonrasib and other KRAS targeting drugs at the 2026 AACR Pancreatic Cancer conference.
Still unconfirmed
- NEAT1-built nuclear structures called paraspeckles determine pancreatic cancer cell identity and resistance to ferroptosis.
What to watch next
- Results from larger clinical trials for the Verastem KRAS G12D pill.
- Development of drug combinations to prevent genetic reshaping and resistance to daraxonrasib.
confidence 90%Sources used for this update (8)
- www.medicaldaily.com — Experimental KRAS G12D Pill Shrank Tumors in 41% of Previously Treated Pancreatic Cancer Patients in Early Trial - Medical Daily
- elderofziyon.blogspot.com — 10/20 Links Pt2: France in Flames: How the Red-Green Alliance Is Undermining Western Democracy; The Money Network Behind Mamdani, ....
- www.massbio.org — Pancreatic cancer has a new drug and women need earlier detection
- jen.jiji.com — "Money will be useless": Elon Musk and the shocking prophecy about robots and AI
- letswinpc.org — 2026 AACR Research Conference - Let's Win Pancreatic Cancer
- memoinoncology.com — After the Standing Ovation: What Changed for RAS Inhibitors ...
- medianewssource.com — Pancreatic Cancer Treatment Enters a New Chapter as Targeted ...
- Bioengineer.org — Hidden RNA Structures in Pancreatic Cancer Cells Reveal New Drug
-
New Insights Reveal How Pancreatic Cancer Evades Daraxonrasib
Researchers have identified two ways pancreatic tumors escape the targeted therapy daraxonrasib through blood tests and biopsies in a preliminary study of 66 patients. Daraxonrasib won FDA clearance in August to block specific gene mutations driving abnormal cell growth, but the medication loses its effect over time in most advanced patients. A new analysis of nearly half a million cells from dozens of patients reveals how cancer cells reshape their genetic makeup over time. These findings point toward potential drug combinations that could extend patient benefits beyond chemotherapy.
Why it matters
Modern oncology has shifted toward considering a tumor's genetic alterations, protein expression, immune environment, molecular subtype, treatment history, and resistance mechanisms rather than just location and stage. Targeted drugs and personalized vaccines are creating new possibilities for pancreatic cancer treatment. A landmark study published on October 13, 2026, in Nature Genetics by researchers at UC San Diego Moores Cancer Center and New York University further unveils how these tumors adapt.
What is confirmed
- Daraxonrasib won FDA clearance in August to block specific gene mutations driving abnormal cell growth.
- A preliminary study of 66 patients used biopsies and blood tests to identify two ways tumors escape daraxonrasib therapy.
- An analysis of nearly half a million cells from dozens of patients shows how cancer cells reshape their genetic makeup over time to evade treatment.
- Researchers at UC San Diego Moores Cancer Center and New York University published a landmark study in Nature Genetics on October 13, 2026.
What to watch next
- Clinical trials testing potential drug combinations to prevent daraxonrasib resistance
- Further developments in personalized vaccines and targeted radiation-based combinations for pancreatic cancer
confidence 100%Sources used for this update (8)
- www.utmb.edu — How new targeted therapies are changing pancreatic cancer ...
- www.managedhealthcareexecutive.com — Daraxonrasib trial exceeds expectations after decades of ...
- standuptocancer.org — Science News | Sustaining Progress against Pancreatic Cancer ...
- www.smartcancer.org — New Cancer Treatment Breakthroughs (2026 Update): The Biggest ...
- www.acumen.news — Pancreatic Cancer's Hidden Shifts: New Study Unlocks Tumor's ...
- medicalxpress.com — Continuously evolving cells help pancreatic cancer evade ...
- www.nature.com — Pancreatic cancer | Nature Reviews Clinical Oncology
- jen.jiji.com — Gasperini: "Dybala will not be there against Slovan, he has a minor injury"
-
Clues to Why Pancreatic Cancer Drug Daraxonrasib Stops Working
Researchers have identified two ways tumors escape the therapy daraxonrasib through biopsies and blood tests in a preliminary study of 66 patients. The findings point toward potential drug combinations that could extend patient benefits. Daraxonrasib, which blocks specific gene mutations driving abnormal cell growth, won FDA clearance in August. However, most patients with advanced pancreatic cancer see the medication lose its effect over time.
Why it matters
Pancreatic cancer is a deadly disease, with nearly 85 percent of people dying within five years of diagnosis. The study's insights into how cancer cells evade treatment could lead to more effective therapies. Daraxonrasib's approval offers new hope, but the medication's limited duration of effectiveness is a significant challenge. Understanding the resistance mechanisms is crucial to improving treatment outcomes.
What is confirmed
- An analysis of nearly half a million cells from dozens of patients' tumors reveals how cancer cells continuously reshape their genetic makeup over time, enabling them to evade treatment.
- Pancreatic ductal adenocarcinoma kills nearly 85 percent of people within five years of diagnosis.
- The study focused on pancreatic ductal adenocarcinoma, an often difficult-to-treat disease.
Still unconfirmed
- Daraxonrasib could transform pediatric cancer treatment and open new doors for targeted therapies in children.
What to watch next
- Further studies on potential drug combinations to extend patient benefits
- FDA decisions on new treatments for pancreatic cancer
- Publication of detailed research findings in a peer-reviewed journal
confidence 85%Sources used for this update (5)
- www.nature.com — RevMed’s pancreatic cancer drug first - Nature Biotechnology
- www.pcrf-kids.org — What is Daraxonrasib? How a New ‘Miracle Drug’ Could ...
- www.prnewswire.com — Continuously Evolving Cells Help Pancreatic Cancer Evade ...
- biotech-today.com — Rasonque Response Gap Leaves Room for Pancreatic Cancer…
- smb.americanpress.com — Continuously Evolving Cells Help Pancreatic Cancer Evade ...
-
Clues Emerge on Why Pancreatic Drug Daraxonrasib Fails
Researchers are uncovering why the pancreatic cancer drug daraxonrasib eventually stops working in advanced patients. A preliminary study examined samples from 66 patients in an early-stage trial, identifying two ways tumors escape the therapy through biopsies and blood tests. This work points toward potential drug combinations that could extend patient benefits. The treatment won FDA clearance in August after blocking specific gene mutations that drive abnormal cell growth. Most patients with advanced pancreatic cancer treated with daraxonrasib ultimately see the medication lose its effect, prompting a race among scientists to understand the resistance mechanisms.
Why it matters
Daraxonrasib targets specific gene mutations driving abnormal cell growth, turning an elusive cancer target into new treatments following decades of NCI-supported research on RAS biology. Understanding how tumors develop resistance is vital to improving long-term outcomes for advanced pancreatic cancer patients who experience treatment failure. Uncovering these evasion pathways paves the way for rational drug combinations designed to outsmart the cancer.
What is confirmed
- Most patients with advanced pancreatic cancer treated with daraxonrasib will see the drug lose its effect.
- Daraxonrasib was cleared by the FDA in August after blocking specific gene mutations that drive abnormal cell growth.
- A preliminary study examined samples from 66 patients in an early-stage trial to uncover how tumors manage to evade treatment.
- Biopsies and blood tests reveal two ways pancreatic tumors escape daraxonrasib, pointing to potential drug combinations.
What to watch next
- Development of clinical trials testing drug combinations based on the two identified tumor escape mechanisms.
- Further peer-reviewed publications detailing the exact genetic or biological pathways of daraxonrasib resistance.
confidence 100%Sources used for this update (5)
- world-today-journal.com — Researchers study why pancreatic cancer patients develop ...
- www.virginislandsdailynews.com — Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually ...
- www.cafepharma.com — Why the breakthrough Revolution Medicines pancreatic cancer ...
- www.cancer.gov — Taking on the RAS Challenge - National Cancer Institute
- pubmed.ncbi.nlm.nih.gov — Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More
-
Clues Emerge on Why Pancreatic Drug Daraxonrasib Stops Working
Biopsies and blood tests reveal two ways pancreatic tumors escape the breakthrough drug daraxonrasib, pointing to potential drug combinations that could extend patient benefits. Researchers are racing to understand why the therapy eventually stops working after showing early promise. Most patients with advanced pancreatic cancer treated with daraxonrasib will see the medication lose its effect. The treatment was cleared by the FDA in August after blocking specific gene mutations that drive abnormal cell growth. A preliminary study examined samples from 66 patients in an early-stage trial to uncover how tumors manage to evade the treatment.
Why it matters
The loss of efficacy in advanced pancreatic cancer treatment poses a major hurdle for novel targeted therapies. Understanding the specific mechanisms of resistance allows scientists to design combination therapies that could extend patient survival. These findings follow an early-stage trial examining patient samples to track resistance patterns.
What is confirmed
- Daraxonrasib was cleared by the FDA in August after blocking specific gene mutations that drive abnormal cell growth.
- A preliminary study examined samples from 66 patients in an early-stage trial to uncover how tumors manage to evade treatment.
- Most patients with advanced pancreatic cancer treated with daraxonrasib will see the drug lose its effect.
- Biopsies and blood tests reveal two ways pancreatic tumors escape daraxonrasib, pointing to potential drug combinations.
Still unconfirmed
- The drug stops working after seven months.
What to watch next
- Results from clinical evaluations of potential drug combinations designed to overcome tumor resistance
- Further data on the exact genetic pathways utilized by tumors to evade daraxonrasib
confidence 90%Sources used for this update (4)
- thegrayvine.com — New Pancreatic Cancer Drug Doubles Survival - but It Stops ...
- oncodaily.com — AACR 2026: Why Do KRAS G12D Pancreatic Tumors Respond ...
- www.thetwin.org — OTHERS: 2026-10-04 | Thet Win
- www.cafepharma.com — Why the breakthrough Revolution Medicines pancreatic cancer ...
-
Clues Emerge on Why Pancreatic Cancer Drug Daraxonrasib Fails
Biopsies and blood tests reveal two ways pancreatic tumors escape the breakthrough drug daraxonrasib, pointing to potential drug combinations that could extend patient benefits. Researchers are racing to understand why the therapy eventually stops working after showing early promise. The medication was cleared by the FDA in August after blocking specific gene mutations that drive abnormal cell growth. A preliminary study examined samples from 66 patients in an early-stage trial to uncover how tumors manage to evade the treatment.
Why it matters
Daraxonrasib is a breakthrough therapy that buys pancreatic cancer patients more time, making resistance a critical hurdle for oncologists. The drug received accelerated FDA approval more than six months ahead of schedule following strong early trial results. Understanding the mechanics of tumor resistance is essential for developing secondary treatments that can sustain patient survival.
What is confirmed
- Biopsies and blood tests reveal two ways pancreatic tumors escape daraxonrasib.
- Daraxonrasib was cleared in August.
Still unconfirmed
- Drug combinations could extend the benefit of daraxonrasib.
What to watch next
- Further clinical trial results testing drug combinations to overcome daraxonrasib resistance
- Additional peer-reviewed publication of the preliminary study data from the 66 patient biopsies
confidence 90%Sources used for this update (3)
- www.newser.com — How a Promising Pancreatic Cancer Drug Loses Its Punch - Newser
- news.ssbcrack.com — Why Breakthrough Pancreatic Cancer Pill Daraxonrasib Stops ...
- article.wn.com — Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually ...
-
Clues Emerge on Why Pancreatic Cancer Drug Daraxonrasib Fails
Researchers are investigating why patients inevitably develop resistance to the breakthrough pancreatic cancer drug daraxonrasib. Developed by the Dana-Farber Cancer Institute and manufactured by Revolution Medicines, the medication works by blocking specific gene mutations that drive abnormal cell growth. The treatment showed so much early promise that the FDA approved it more than six months ahead of schedule. However, patients eventually stop responding to the therapy. A preliminary study recently examined biopsies from 66 patients in an early-stage trial to uncover how tumors manage to evade the drug.
Why it matters
Pancreatic cancer has historically presented immense treatment challenges, making the arrival of a drug capable of targeting core genetic drivers a significant milestone. The FDA expedited approval of daraxonrasib due to its promising initial performance against advanced disease. Despite this early success, understanding resistance mechanisms is vital to prolonging patient responses and improving long-term survival outcomes.
What is confirmed
- Daraxonrasib was developed by the Dana-Farber Cancer Institute.
- The FDA approved daraxonrasib more than six months ahead of schedule.
- Revolution Medicines produces daraxonrasib.
- A preliminary study analyzed biopsies from 66 patients enrolled in an early-stage trial.
Still unconfirmed
- Former Senator Ben Sasse is among the patients who developed resistance to daraxonrasib.
What to watch next
- Further findings from the ongoing analysis of patient biopsies from the early-stage trial
- Clinical developments targeting how pancreatic tumors evade daraxonrasib treatment
confidence 90%Sources used for this update (13)
- www.wbur.org — How an Mass. researcher's lab made a breakthrough in pancreatic cancer treatment
- The New York Times — Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working
- WBUR — How a Mass. researcher's lab made a breakthrough in pancreatic cancer treatment
- Gizmodo — This Pill Will Change Cancer Treatment Forever
- Arizona PBS — Arizona’s connection to a new pancreatic cancer treatment
- GlobeNewswire — AIM ImmunoTech Discusses Ampligen®’s Potential to
- medscape.com — How Scientists Finally Cracked RAS in Pancreatic Cancer
- www.adamkinzinger.com — BREAKING: Trump Approval Hits Record Low, Elon Musk Gets Job At Pentagon, Trump Surrenders To AI Giants, ....
- flipboard.com — This Pill Will Change Cancer Treatment Forever
- article.wn.com — Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually ...
- www.zetik.com — Researchers Trace Daraxonrasib Resistance in 66 Pancreatic ...
- singlinkbot.com — Why Breakthrough Pancreatic Cancer Drug Eventually Fails ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community